BioXcel Therapeutics (BTAI) Operating Leases (2019 - 2024)
BioXcel Therapeutics' (BTAI) quarterly Operating Leases came in at $65000.0 in Q4 2024, down 85.23% year-on-year from $440000.0 in Q1 2024, and down 59.63% quarter-over-quarter from $161000.0 in Q3 2024.
BioXcel Therapeutics (BTAI) Operating Leases (2019 - 2024) Analysis & Trends
BioXcel Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $65000.0 for Q4 2024.
- On a quarterly basis, Operating Leases fell 85.23% year-over-year to $65000.0 in Q4 2024; TTM through Dec 2024 was $65000.0, a 85.23% decrease from a year earlier, with the FY2024 full-year figure at $65000.0, down 85.23% from the prior year.
- Operating Leases retreated to $65000.0 in Q4 2024 per BTAI's latest filing, from $161000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $1.5 million in Q3 2020 and bottomed at $65000.0 in Q4 2024.
- The 5-year median for Operating Leases is $887500.0 (2020), against an average of $817650.0.
- Across the five-year window, Operating Leases soared 38.37% in 2021 and tumbled 85.23% in 2024, its largest moves.
- Year by year, Operating Leases stood at $1.4 million in 2020, then declined by 20.96% to $1.1 million in 2021, then fell by 28.87% to $786000.0 in 2022, then sank by 44.02% to $440000.0 in 2023, then tumbled by 85.23% to $65000.0 in 2024.
- Per Business Quant, the three latest BTAI Operating Leases figures stand at $65000.0 (Q4 2024), $161000.0 (Q3 2024), and $256000.0 (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 65,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 256,000.00 |
| Mar 31, 2024 | 350,000.00 |
| Dec 31, 2023 | 440,000.00 |
| Sep 30, 2023 | 529,000.00 |
| Jun 30, 2023 | 617,000.00 |
| Mar 31, 2023 | 703,000.00 |
| Dec 31, 2022 | 786,000.00 |
| Sep 30, 2022 | 868,000.00 |
| Jun 30, 2022 | 949,000.00 |
| Mar 31, 2022 | 1.03 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | 1.18 Mn |
| Jun 30, 2021 | 1.26 Mn |
| Mar 31, 2021 | 1.33 Mn |
| Dec 31, 2020 | 1.40 Mn |
| Sep 30, 2020 | 1.47 Mn |
| Jun 30, 2020 | 907,000.00 |
| Mar 31, 2020 | 961,000.00 |